AxoGen, Inc. (AXGN) Stock Analysis
Healthcare · Medical Devices
Sell if holding. Engine safety override at $43.07: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 5.7/10. Specifically: Below-average business quality.
AxoGen is focused on peripheral nerve regeneration and repair, commercializing the FDA-approved Avance Nerve Graft (acellular nerve allograft), Axoguard Nerve Connector, Nerve Protector, Nerve Cap, and Avive+ Soft Tissue Matrix, primarily in the US. Avance Products represent... Read more
Sell if holding. Engine safety override at $43.07: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 5.7/10. Specifically: Below-average business quality. Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Score 5.7/10, moderate confidence.
Passes 6/7 gates (positive momentum, clean insider activity, no SEC red flags, news boost analyst 0.50, earnings proximity 95d clear, semi cycle peak clear). Fails on favorable risk/reward ratio. Suitability: aggressive.
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHProductAvance Products60%10-K Item 1A: 'Approximately 60% of our total revenues are from sales of Avance Products'
- MEDIUMSupplierEvergen10-K Item 1A: 'Axoguard Nerve Connector and Axoguard Nerve Protector are only available through a distribution agreement with Evergen.'
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer
Rating Breakdown
3 floor-breakers·1 ceiling hit
Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static
Unprofitable operations — net margin -13.2%. Quality floor flags this regardless of sector context.static
Technicals below the gate floor. Component breakdown shows what dragged the score down.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $43.07: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 5.7/10. Specifically: Below-average business quality. Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Prior stop was $40.05. Score 5.7/10, moderate confidence.
Take-profit target: $44.91 (+4.3% upside). Prior stop was $40.05. Stop-loss: $40.05.
Concentration risk — Product: Avance Products (60.0%); Target reached (-1.2% upside); Quality below floor (3.8 < 4.0).
AxoGen, Inc. trades at a P/E of N/A (forward 56.7). TrendMatrix value score: 4.7/10. Verdict: Sell.
16 analysts cover AXGN with a consensus score of 4.2/5. Average price target: $49.
What does AxoGen, Inc. do?AxoGen is focused on peripheral nerve regeneration and repair, commercializing the FDA-approved Avance Nerve Graft...
AxoGen is focused on peripheral nerve regeneration and repair, commercializing the FDA-approved Avance Nerve Graft (acellular nerve allograft), Axoguard Nerve Connector, Nerve Protector, Nerve Cap, and Avive+ Soft Tissue Matrix, primarily in the US. Avance Products represent approximately 60% of total revenues.